Telomir Pharmaceuticals, Inc. Common Stock reported earnings of -$ 0.01 per TELO share on Nov 6, 2026, falling short of analysts' expectations by
| Report Date | Nov 6, 2026 |
|---|---|
| Forecasted EPS | -$ 0.03 |
| Earnings Per Share (Surprise) | -$ 0.01 (+$ 0.02) |
| Last Year's EPS | -$ 0.08 |
| EPS YoY Change |
Out of the last 20 earnings reporting periods, Telomir Pharmaceuticals, Inc. Common Stock beat analysts’ expectations 6 times and fell short of expectations 4 time(s). Telomir Pharmaceuticals, Inc. Common Stock reported earnings per share of -$ 0.01 in the last report surpassing an estimated EPS of -$ 0.03 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 6, 2026 | -$ 0.03 | -$ 0.01 | -$ 0.06 | |
| Aug 13, 2026 | -$ 0.07 | -$ 0.79 | -$ 0.03 | |
| May 14, 2026 | -$ 0.07 | -$ 0.03 | -$ 0.17 | |
| May 13, 2026 | -$ 0.07 | -$ 0.03 | -$ 0.07 | |
| Mar 17, 2026 | -$ 0.07 | -$ 0.06 | -$ 0.10 | |
| Nov 10, 2025 | -$ 0.07 | -$ 0.03 | -$ 0.20 | |
| Aug 14, 2025 | -$ 0.08 | -$ 0.17 | -$ 0.05 | |
| May 14, 2025 | -$ 0.10 | -$ 0.07 | -$ 0.23 | |
| Feb 4, 2025 | -$ 0.05 | -$ 0.10 | -$ 0.32 | |
| Nov 12, 2024 | -$ 0.05 | -$ 0.20 | -$ 0.06 | |
| Aug 13, 2024 | - | -$ 0.05 | -$ 0.05 | |
| May 13, 2024 | - | -$ 0.23 | -$ 0.02 | |
| Mar 29, 2024 | - | -$ 0.32 | -$ 0.02 | |
| Sep 30, 2023 | - | -$ 0.06 | -$ 0.01 | |
| Jun 30, 2023 | - | -$ 0.05 | $ 0.00 | |
| Mar 31, 2023 | - | -$ 0.02 | $ 0.00 | |
| Dec 31, 2022 | - | -$ 0.02 | - | - |
| Sep 29, 2022 | - | -$ 0.01 | - | - |
| Jun 29, 2022 | - | $ 0.00 | - | - |
| Mar 31, 2022 | - | $ 0.00 | - | - |
Telomir Pharmaceuticals, Inc. Common Stock’s stock was trading at $ 0.7801 on Nov 5, 2026 a day before the last earnings report was released.Following the release of the earnings report, TELO’s price decreased to $ 0.69 on Nov 7, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 6, 2026 | -$ 0.01 | $ 0.7801 | $ 0.69 | |
| Aug 13, 2026 | -$ 0.79 | $ 1.11 | $ 1.09 | |
| May 14, 2026 | -$ 0.03 | $ 1.23 | $ 1.26 | |
| May 13, 2026 | -$ 0.03 | $ 1.26 | $ 1.27 | |
| Mar 17, 2026 | -$ 0.06 | $ 1.34 | $ 1.27 | |
| Nov 10, 2025 | -$ 0.03 | $ 1.31 | $ 1.42 | |
| Aug 14, 2025 | -$ 0.17 | $ 1.60 | $ 1.49 | |
| May 14, 2025 | -$ 0.07 | $ 2.75 | $ 2.36 | |
| Feb 4, 2025 | -$ 0.10 | $ 4.17 | $ 4.65 | |
| Nov 12, 2024 | -$ 0.20 | $ 4.38 | $ 3.98 | |
| Aug 13, 2024 | -$ 0.05 | $ 4.96 | $ 3.81 | |
| May 13, 2024 | -$ 0.23 | $ 6.91 | $ 6.31 | |
| Mar 29, 2024 | -$ 0.32 | $ 5.15 | $ 5.46 |
Telomir Pharmaceuticals, Inc. Common Stock released its most recent earnings reports in November 2026, August 2026, May 2026, May 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Telomir Pharmaceuticals, Inc. Common Stock beat analysts’ expectations during the last earnings period by
